

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Vaccine 40 (2022) 7009



Contents lists available at ScienceDirect

Vaccine



journal homepage: www.elsevier.com/locate/vaccine

Corrigendum

Corrigendum to "Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein" [Vaccine 40(20) (2022) 2856–2868]



Mohammad Hassan Pouriayevali ^{a,b}, Ali Teimoori ^c, Saber Esmaeili ^{d,e}, Asghar Abdoli ^{f,g}, Delaram Doroud ^h, Mostafa Salehi-Vaziri ^{a,b}, Maryam Shahali ⁱ, Maryam Kadkhodazadeh ^j, Talieh Sabouni ^h, Mohammad Ali Khosravi ⁱ, Mohammad Panahi ⁱ, Fereidoon Khoshroo ⁱ, Anahita Bahmanjeh ⁱ, Yury Valdes-Balbin ^k, Dagmar Garcia-Rivera ^k, Vicente Verez-Bencomo ^k, Alireza Biglari ^{l,*}, Kazem Baesi ^{f,*}

^a COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran

^b Department of Arboviruses and Viral Hemorrhagic Fevers (National Reference Laboratory), Pasteur Institute of Iran, Tehran, Iran

^c Department of Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

^d National Reference Laboratory for Plague, Tularemia and Q Fever, Research Center for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Akanlu, Kabudar Ahang, Hamadan, Iran

e Department of Epidemiology and Biostatistics, Research Center for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran

^fDepartment of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran

^g Amirabad Virology Laboratory, Vaccine Unit, Tehran, Iran

^h Research and Production Complex, Pasteur Institute of Iran, Tehran, Iran

ⁱ Department of Production, Research and Production Complex, Pasteur Institute of Iran, Tehran, Iran

^j Department of Molecular Virology, Pasteur Institute of Iran, Tehran, Iran

^k Finlay Vaccine Institute, Havana, Cuba

¹Pasteur Institute of Iran, Tehran, Iran

The authors regret that the names in the title page were submitted as last name then first name and this has prevented the article from being tagged correctly.

The names have now been changed and have been correctly tagged as above.

The authors would like to apologise for any inconvenience caused.

E-mail addresses: biglari63@hotmail.com (A. Biglari), k_baesi@pasteur.ac.ir (K. Baesi).

DOI of original article: https://doi.org/10.1016/j.vaccine.2022.03.066

^{*} Corresponding authors at: Head of Pasteur Institute of Iran, P.O. Box 14115-331, Tehran, Iran (B. Alireza). Department of Hepatitis and AIDS, Pasteur Institute of Iran, P.O. Box 14115-331, Tehran, Iran (B. Kazem).